Activity of tunicamycin against Trypanosoma brucei in vitro and in vivo.

AUTOR(ES)

Casero, R A

RESUMO

Tunicamycin, a specific inhibitor of glycoprotein biosynthesis, was evaluated for activity and chemotherapeutic potential against Trypanosoma brucei in vitro and in vivo. The inhibition of parasite incorporation of two radiolabeled macromolecular precursors, [methyl-3H]thymidine and D-[2-3H]mannose, was measured in short-term (4-h) microcultures. Mannose incorporation was inhibited over the concentration range of 0.01 to 10.0 microgram/ml, reaching 60% at the latter level. Thymidine incorporation was not affected. In vivo experiments indicated that a single dose of 2.0 mg of tunicamycin per kg can cure or significantly increase the life-span of mice of three different strains, each infected with T. brucei.

Documentos Relacionados

• In Vitro and In Vivo Activities of Aminoadamantane and Aminoalkylcyclohexane Derivatives against Trypanosoma brucei
• Glutathione Derivatives Active against Trypanosoma brucei rhodesiense and T. brucei brucei In Vitro
• Activity of clindamycin with primaquine against Pneumocystis carinii in vitro and in vivo.
• Activity of (+)-cyclaradine (Sch 31172) against herpes simplex virus in vitro and in vivo.
• Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo.